Women's International Pharmacy: Safety, Regulation & Compliance Posture

What Is Women's International Pharmacy?

Women's International Pharmacy is a compounding pharmacy headquartered in Madison, Wisconsin, with a second location in Woodland Hills, California. The pharmacy has operated for over four decades, specializing in custom-compounded bioidentical hormone preparations for women and men. Its product catalog includes compounded estradiol, progesterone, testosterone, DHEA, and thyroid formulations in various delivery forms (capsules, creams, troches, suppositories).

WIP operates under a 503A designation, meaning it compounds patient-specific prescriptions rather than manufacturing drugs in bulk without prescriptions. This distinction matters. Under the Drug Quality and Security Act of 2013, 503A pharmacies are exempt from FDA current Good Manufacturing Practice (cGMP) requirements and pre-market approval, provided they compound in response to individual prescriptions [1]. State boards of pharmacy serve as the primary regulators. WIP is not an FDA-registered outsourcing facility (503B), which would subject it to more rigorous federal oversight and cGMP standards.

The pharmacy holds accreditation from the Pharmacy Compounding Accreditation Board (PCAB), a voluntary credential that signals adherence to quality benchmarks beyond state minimums [2]. PCAB accreditation is not a federal requirement.

How Compounding Pharmacies Are Regulated

The regulatory framework for compounding pharmacies sits between two federal statutes and a patchwork of 50 state pharmacy boards. That framework has real gaps.

Section 503A of the Federal Food, Drug, and Cosmetic Act exempts traditional compounding pharmacies from three FDA requirements: cGMP compliance, labeling with adequate directions for use, and FDA pre-market approval [1]. The tradeoff is that 503A pharmacies must compound based on a valid patient-specific prescription, use ingredients that meet USP or National Formulary standards, and comply with state pharmacy law. The FDA's page on compounding notes that compounded drugs "are not FDA-approved" and that the agency "generally defers to state authorities" regarding 503A pharmacies [3].

State board inspections vary widely in frequency and rigor. A 2019 Pew Charitable Trusts analysis found that inspection intervals ranged from annual to once every several years, and that 28 states lacked the authority to require sterile compounders to report adverse events [4]. Wisconsin, where WIP's primary facility is located, requires annual inspections for pharmacies holding sterile compounding licenses.

For context on why this matters: the 2012 New England Compounding Center (NECC) meningitis outbreak, which killed 76 people and sickened 793 from contaminated methylprednisolone injections, was the catalyst for the DQSA [5]. That disaster exposed how a compounding pharmacy operating in a regulatory gray zone between state and federal oversight could cause mass harm.

USP Compounding Standards and What They Require

WIP must comply with USP General Chapters 795 (non-sterile compounding) and 797 (sterile compounding). These set minimum standards for personnel training, facility design, beyond-use dating, and quality assurance.

USP 795, revised in November 2023, requires compounders to assign beyond-use dates based on stability data or default conservative limits, maintain master formulation records, and perform periodic quality checks [6]. USP 797, which took effect November 1, 2023 after years of delays, tightens requirements for sterile preparations including environmental monitoring, personnel garbing, and shortened beyond-use dates for certain risk categories [7].

A critical point: compliance with USP standards is self-reported and enforced at the state level. Unlike FDA-approved manufacturers who undergo pre-approval inspections and ongoing cGMP audits, compounding pharmacies are not required to submit potency or sterility data to a federal agency. The FDA has stated that "there is generally less assurance" that compounded drugs meet the quality standards of commercially manufactured products [3].

PCAB Accreditation: What It Does and Does Not Guarantee

WIP's PCAB accreditation is often cited in its marketing as a quality differentiator. That claim deserves context. PCAB, now administered by the Accreditation Commission for Health Care (ACHC), evaluates pharmacies against criteria that include adherence to USP compounding chapters, staff training documentation, quality control procedures, and facility standards [2].

PCAB accreditation is voluntary. Fewer than 400 pharmacies in the United States hold it. The accreditation process involves an on-site survey and periodic re-evaluation. It represents a higher bar than the statutory minimum.

But accreditation is not equivalence to FDA approval. PCAB does not review or approve individual formulations. It does not require bioequivalence testing. It does not mandate the kind of stability studies that FDA requires for approved drug products. Dr. Steven Nissen, a cardiologist at Cleveland Clinic, noted in a 2020 commentary that "compounded drugs lack the quality assurance processes that protect patients receiving FDA-approved medications" [8].

The FDA's Position on Compounded BHRT

The FDA has taken a consistent position against compounded bioidentical hormones for over a decade. In a 2008 statement the agency warned that claims of superior safety for "bioidentical" compounded hormones over FDA-approved hormones are unsupported by clinical evidence [9].

This is not a theoretical concern. Several FDA-approved bioidentical hormone products already exist. Estradiol patches (Climara, Vivelle-Dot), oral micronized progesterone (Prometrium), and estradiol vaginal preparations (Vagifem, Imvexxy) all contain the same bioidentical molecules that compounding pharmacies use. The difference is that these products have undergone Phase III clinical trials, bioequivalence testing, and cGMP manufacturing oversight.

The Endocrine Society's 2017 Scientific Statement on compounded bioidentical hormones concluded that "there is no evidence that these preparations are safer or more efficacious than government-approved hormonal therapies" [10]. The statement also raised concerns about batch-to-batch variability in compounded products, noting that "content analysis of compounded preparations has shown variability in hormone concentrations."

The North American Menopause Society (NAMS) echoed this in its 2022 hormone therapy position statement, recommending FDA-approved products as first-line therapy and noting that "custom-compounded hormones pose additional risks including variable purity, potency, and quality" [11].

Potency and Consistency Concerns

One of the most cited safety concerns with compounded hormones is batch-to-batch variability. A study published in the Journal of Clinical Pharmacology (Jiang et al., 2021) analyzed compounded testosterone and progesterone preparations from multiple pharmacies and found that 34.5% of tested samples fell outside the acceptable potency range of 90% to 110% of the labeled dose [12]. Some samples contained as little as 67.5% of the intended dose.

This is not unique to any single pharmacy, and it does not mean WIP's products specifically have failed potency testing. WIP has not published independent third-party potency analyses of its formulations. The absence of publicly available batch data is itself a limitation that patients and prescribers should weigh.

By comparison, FDA-approved hormone products must demonstrate batch-to-batch consistency within 90% to 110% of labeled potency as a condition of approval, and manufacturers face consequences for deviations [13]. The FDA's cGMP regulations (21 CFR Parts 210 and 211) require testing of every batch before release.

How WIP Compares to FDA-Approved BHRT Alternatives

The comparison between WIP's compounded formulations and FDA-approved bioidentical hormones is not a matter of molecule identity. Both use estradiol, progesterone, and testosterone derived from plant precursors. The divergence is in manufacturing oversight, testing requirements, and clinical evidence.

FDA-approved bioidentical options include estradiol patches producing serum levels of 25 to 100 pg/mL depending on dose, oral micronized progesterone (Prometrium, 100 mg and 200 mg capsules), and testosterone for women (currently off-label use of low-dose FDA-approved male formulations, since no female testosterone product is FDA-approved in the U.S.) [14]. The WHI follow-up data from 18 years of cumulative follow-up in 27,347 women confirmed that estrogen-alone therapy (conjugated equine estrogens) was associated with significantly lower breast cancer incidence compared to placebo [15].

Where compounding fills a legitimate gap: some patients need dosage forms, combinations, or allergen-free bases not commercially available. A woman who needs a specific estradiol-to-estriol ratio, or who has allergies to excipients in FDA-approved products, may have no alternative to compounding. The American College of Obstetricians and Gynecologists (ACOG) acknowledges this limited role in its Committee Opinion 532, stating that compounding is appropriate "when a patient has a legitimate medical need for a medication that is not commercially available" [16].

Dr. JoAnn Manson, chief of preventive medicine at Brigham and Women's Hospital and a principal investigator of the Women's Health Initiative, stated in a 2020 JAMA editorial that "the use of compounded hormones in preference to FDA-approved hormones should be discouraged unless there is a specific clinical indication" [8].

What "Legit" Means in the Context of Compounding

The question "Is Women's International Pharmacy legit?" appears frequently in online searches. The answer depends on what standard you apply.

WIP is a legally licensed, PCAB-accredited compounding pharmacy with decades of continuous operation. It requires valid prescriptions. It employs licensed pharmacists. By the standard of operating within the law, it is legitimate.

By the standard of FDA-approved pharmaceutical manufacturers, no compounding pharmacy, including WIP, meets the same evidentiary and manufacturing bar. Compounded products are not tested for bioequivalence. They do not carry FDA-approved labeling. Their adverse-event reporting is not mandatory under federal law (though some states require it).

The legitimate question is not whether WIP is a scam. It is whether a compounded hormone preparation is the right clinical choice for a given patient when an FDA-approved bioidentical alternative exists. For most patients, professional society guidelines say no. For a defined subset with specific needs unmet by commercial products, compounding remains a valid option.

Patient Safety Checklist Before Using Any Compounding Pharmacy

Patients considering WIP or any compounding pharmacy for hormone therapy should verify several things. Ask whether the pharmacy holds PCAB accreditation or equivalent voluntary quality certification. Confirm that the prescribing clinician has reviewed FDA-approved alternatives first. Request a copy of the pharmacy's most recent state board inspection report. Ask whether the pharmacy conducts third-party potency testing of its preparations and whether it will share those results.

Patients taking compounded hormones should have serum hormone levels checked 4 to 8 weeks after starting therapy and at least annually thereafter, per Endocrine Society monitoring recommendations [17]. Unexplained symptom changes or lab values outside expected ranges may signal potency variability and warrant a conversation with the prescriber about switching to an FDA-approved formulation.